Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

894 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H; Treating to New Targets (TNT) Steering Committee and Investigators. LaRosa JC, et al. Among authors: kastelein jj. Am J Cardiol. 2007 Sep 1;100(5):747-52. doi: 10.1016/j.amjcard.2007.03.102. Epub 2007 Jun 14. Am J Cardiol. 2007. PMID: 17719314 Clinical Trial.
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy.
Semb AG, van Wissen S, Ueland T, Smilde T, Waehre T, Tripp MD, Frøland SS, Kastelein JJ, Gullestad L, Pedersen TR, Aukrust P, Stalenhoef AF. Semb AG, et al. Among authors: kastelein jj. J Am Coll Cardiol. 2003 Jan 15;41(2):275-9. doi: 10.1016/s0735-1097(02)02718-3. J Am Coll Cardiol. 2003. PMID: 12535822 Free article. Clinical Trial.
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study.
Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Palmer G; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Pedersen TR, et al. Among authors: kastelein jj. Am J Cardiol. 2004 Sep 15;94(6):720-4. doi: 10.1016/j.amjcard.2004.06.003. Am J Cardiol. 2004. PMID: 15374773 Clinical Trial.
Safety of rosuvastatin.
Shepherd J, Hunninghake DB, Stein EA, Kastelein JJ, Harris S, Pears J, Hutchinson HG. Shepherd J, et al. Among authors: kastelein jj. Am J Cardiol. 2004 Oct 1;94(7):882-8. doi: 10.1016/j.amjcard.2004.06.049. Am J Cardiol. 2004. PMID: 15464670 Clinical Trial.
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. LaRosa JC, et al. Among authors: kastelein jj. N Engl J Med. 2005 Apr 7;352(14):1425-35. doi: 10.1056/NEJMoa050461. Epub 2005 Mar 8. N Engl J Med. 2005. PMID: 15755765 Free article. Clinical Trial.
Atorvastatin.
van Leuven SI, Kastelein JJ. van Leuven SI, et al. Among authors: kastelein jj. Expert Opin Pharmacother. 2005 Jun;6(7):1191-203. doi: 10.1517/14656566.6.7.1191. Expert Opin Pharmacother. 2005. PMID: 15957972 Review.
894 results